D. E. Shaw & Co. Inc. Purchases 471,111 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

D. E. Shaw & Co. Inc. boosted its position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 240.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 666,885 shares of the company’s stock after purchasing an additional 471,111 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Scholar Rock were worth $28,823,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC grew its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after buying an additional 766 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after acquiring an additional 620 shares in the last quarter. Finally, KBC Group NV bought a new stake in shares of Scholar Rock during the 4th quarter valued at about $131,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of Scholar Rock stock opened at $30.85 on Friday. The firm has a market capitalization of $2.93 billion, a PE ratio of -13.13 and a beta of 0.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The business’s 50-day moving average price is $31.63 and its 200-day moving average price is $35.87.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the completion of the sale, the insider now directly owns 111,084 shares in the company, valued at $4,154,541.60. This represents a 38.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the transaction, the chief financial officer now owns 140,740 shares in the company, valued at approximately $5,183,454.20. This represents a 5.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 255,231 shares of company stock worth $9,220,236 over the last ninety days. Insiders own 13.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush restated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.